IN2012DN02487A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02487A IN2012DN02487A IN2487DEN2012A IN2012DN02487A IN 2012DN02487 A IN2012DN02487 A IN 2012DN02487A IN 2487DEN2012 A IN2487DEN2012 A IN 2487DEN2012A IN 2012DN02487 A IN2012DN02487 A IN 2012DN02487A
- Authority
- IN
- India
- Prior art keywords
- enantiomers
- esters
- useful
- formula
- pharmaceutically acceptable
- Prior art date
Links
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
There are provided compounds of the formula wherein X, Y, R1, R2, R3, R3, R4, and R5 are as described herein and enantiomers and pharmaceutically acceptable salts and esters thereof which are useful as anticancer agents.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25141309P | 2009-10-14 | 2009-10-14 | |
| US34562610P | 2010-05-18 | 2010-05-18 | |
| PCT/EP2010/065159 WO2011045257A1 (en) | 2009-10-14 | 2010-10-11 | Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN02487A true IN2012DN02487A (en) | 2015-08-28 |
Family
ID=43567698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2487DEN2012 IN2012DN02487A (en) | 2009-10-14 | 2010-10-11 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8017607B2 (en) |
| EP (1) | EP2488491A1 (en) |
| JP (1) | JP2013507416A (en) |
| KR (1) | KR20120081210A (en) |
| CN (1) | CN102548963A (en) |
| AU (1) | AU2010305914A1 (en) |
| BR (1) | BR112012008485A2 (en) |
| CA (1) | CA2774512A1 (en) |
| IL (1) | IL218018A0 (en) |
| IN (1) | IN2012DN02487A (en) |
| MX (1) | MX2012003982A (en) |
| WO (1) | WO2011045257A1 (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2952522B1 (en) | 2007-01-31 | 2019-10-30 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| AU2008232709C1 (en) | 2007-03-28 | 2015-01-15 | President And Fellows Of Harvard College | Stitched polypeptides |
| US8354444B2 (en) * | 2008-09-18 | 2013-01-15 | Hoffmann-La Roche Inc. | Substituted pyrrolidine-2-carboxamides |
| US20110118283A1 (en) * | 2009-11-17 | 2011-05-19 | Qingjie Ding | Substituted Pyrrolidine-2-Carboxamides |
| KR20170058446A (en) | 2010-08-13 | 2017-05-26 | 에일러론 테라퓨틱스 인코포레이티드 | Peptidomimetic macrocycles |
| WO2012076513A1 (en) * | 2010-12-09 | 2012-06-14 | F. Hoffmann-La Roche Ag | 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer |
| AU2012226890B2 (en) | 2011-03-10 | 2016-10-06 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
| AR088392A1 (en) | 2011-10-18 | 2014-05-28 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCICLES |
| CA2862038C (en) | 2012-02-15 | 2021-05-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| TWI586668B (en) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | Crystals of dispiropyrrolidine derivative |
| BR112015009470A2 (en) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | disubstituted amino acids and their methods of preparation and use |
| TW201429969A (en) | 2012-12-20 | 2014-08-01 | Merck Sharp & Dohme | Substituted imidazolium as an HDM2 inhibitor |
| WO2016049359A1 (en) | 2014-09-24 | 2016-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
| US10253067B2 (en) | 2015-03-20 | 2019-04-09 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018528217A (en) | 2015-09-10 | 2018-09-27 | エルロン・セラピューティクス・インコーポレイテッドAileron Therapeutics,Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| EP3458101B1 (en) | 2016-05-20 | 2020-12-30 | H. Hoffnabb-La Roche Ag | Protac antibody conjugates and methods of use |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0947511A1 (en) | 1998-03-30 | 1999-10-06 | F. Hoffmann-La Roche Ag | Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity |
| NZ516452A (en) | 1999-07-21 | 2004-06-25 | Astrazeneca Ab | Spirooxindole Derivatives |
| WO2005099687A2 (en) | 2004-04-09 | 2005-10-27 | President And Fellows Of Harvard College | Analogs of salinosporamide a |
| US7423051B2 (en) | 2004-07-15 | 2008-09-09 | Hoffmann-La Roche Inc. | 2,6-diaminopyridine derivatives |
| KR100944301B1 (en) | 2005-02-22 | 2010-02-24 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | Small molecule inhibitors of MDM2 and uses thereof |
| BRPI0710477A2 (en) | 2006-01-18 | 2011-08-16 | Hoffmann La Roche | cis-4,5-biaryl - 2-heterocyclic imidazolines as mdm2 inhibitors |
| CN101595107A (en) | 2006-06-30 | 2009-12-02 | 先灵公司 | Substituted piperidines capable of improving P53 activity and uses thereof |
| AU2009294673B2 (en) | 2008-09-18 | 2014-08-14 | F. Hoffmann-La Roche Ag | Substituted pyrrolidine-2-carboxamides |
-
2010
- 2010-10-06 US US12/898,974 patent/US8017607B2/en not_active Expired - Fee Related
- 2010-10-11 EP EP10768450A patent/EP2488491A1/en not_active Withdrawn
- 2010-10-11 AU AU2010305914A patent/AU2010305914A1/en not_active Abandoned
- 2010-10-11 BR BR112012008485A patent/BR112012008485A2/en not_active IP Right Cessation
- 2010-10-11 MX MX2012003982A patent/MX2012003982A/en not_active Application Discontinuation
- 2010-10-11 CA CA2774512A patent/CA2774512A1/en not_active Abandoned
- 2010-10-11 JP JP2012533592A patent/JP2013507416A/en active Pending
- 2010-10-11 IN IN2487DEN2012 patent/IN2012DN02487A/en unknown
- 2010-10-11 KR KR1020127012100A patent/KR20120081210A/en not_active Ceased
- 2010-10-11 WO PCT/EP2010/065159 patent/WO2011045257A1/en not_active Ceased
- 2010-10-11 CN CN2010800461741A patent/CN102548963A/en active Pending
-
2012
- 2012-02-09 IL IL218018A patent/IL218018A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012003982A (en) | 2012-05-08 |
| KR20120081210A (en) | 2012-07-18 |
| US20110086854A1 (en) | 2011-04-14 |
| WO2011045257A1 (en) | 2011-04-21 |
| JP2013507416A (en) | 2013-03-04 |
| IL218018A0 (en) | 2012-04-30 |
| CA2774512A1 (en) | 2011-04-21 |
| CN102548963A (en) | 2012-07-04 |
| US8017607B2 (en) | 2011-09-13 |
| BR112012008485A2 (en) | 2019-09-24 |
| AU2010305914A1 (en) | 2012-03-08 |
| EP2488491A1 (en) | 2012-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN02487A (en) | ||
| MY165238A (en) | Substituted pyrrolidine-2-carboxamides | |
| MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
| MX2014014229A (en) | Substituted pyrrolidine-2-carboxamides. | |
| MY160596A (en) | Spiroindolinone pyrrolidines | |
| TW200801000A (en) | Spiroindolinone derivatives | |
| IL205354A0 (en) | Spiroindolinone derivatives | |
| PH12014501542B1 (en) | Substituted pyrrolidine -2- carboxamides | |
| IL193620A0 (en) | Spiroindolinone derivatives | |
| IL205506A0 (en) | Spiroindolinone derivatives as anticancer agents | |
| MX2011008176A (en) | 3, 3' -spiroindolinone derivatives as anticancer agents. | |
| MX341133B (en) | Compounds and methods. | |
| MX2012008141A (en) | Compounds and methods. | |
| MX2014014531A (en) | Aminoquinazoline and pyridopyrimidine derivatives. | |
| IL208025A0 (en) | Spiroindolinone derivatives | |
| MX2011007886A (en) | Spiroindolinone pyridine derivative. | |
| WO2014062838A3 (en) | Pkm2 modulators and methods for their use | |
| TN2012000105A1 (en) | Spirolactam derivatives and uses of same | |
| MX2014015345A (en) | Pyranopyridone inhibitors of tankyrase. | |
| MX2012005155A (en) | Quinazoline compounds. | |
| MX2013009386A (en) | New azaspirodecanone compounds. | |
| IN2013CN00515A (en) | ||
| MX2013013021A (en) | New hexahydropyrroloimidazolone compounds. | |
| MX2010008778A (en) | 3-alkyl-piperazine derivatives and uses thereof. | |
| UA103497C2 (en) | Substituted pyrrolidine-2-carboxamides |